Leeward Investments LLC MA Sells 3,172 Shares of Hologic, Inc. $HOLX

Leeward Investments LLC MA reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 163,443 shares of the medical equipment provider’s stock after selling 3,172 shares during the quarter. Leeward Investments LLC MA’s holdings in Hologic were worth $10,650,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Chung Wu Investment Group LLC bought a new position in Hologic during the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the 1st quarter valued at approximately $34,000. Cromwell Holdings LLC raised its holdings in shares of Hologic by 307.0% in the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares in the last quarter. Finally, Allworth Financial LP increased its stake in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 216 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on HOLX shares. Leerink Partners upped their price target on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. UBS Group upped their price target on shares of Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research report on Thursday, July 31st. Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research note on Thursday, July 31st. Finally, Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $79.23.

Hologic Stock Up 0.1%

Hologic stock opened at $73.99 on Friday. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company’s 50-day moving average price is $67.65 and its two-hundred day moving average price is $63.99. The stock has a market cap of $16.46 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 2.54 and a beta of 0.63. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the company posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.